International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a project that brings together the regulatory authorities of
Europe, Japanand the United Statesand experts from the pharmaceutical industryin the three regions to discuss scientific and technical aspects of pharmaceutical product registration.
The purpose of ICH is to reduce or obviate the need to duplicate the testing carried out during the research and development of new medicines by recommending ways to achieve greater harmonisation in the interpretation and application of technical guidelines and requirements for product registration.
Harmonisation would lead to a more economical use of human, animal and material resources, and the elimination of unnecessary delay in the global development and availability of new medicines while maintaining safeguards on quality, safety, and efficacy, and regulatory obligations to protect public health.
In the 1980s, what is today the
European Unionbegan harmonising regulatory requirements. In 1989, Europe, Japan, and the United States began creating plans for harmonisation; ICH was created in April 1990 at a meeting in Brussels, Europe.
Seven parties that represent the regulatory bodies and the research-based industries of the founding members are responsible for the decision making process: the
European Commission, the European Medicines Agency(EMEA), the European Federation of Pharmaceutical Industries and Associations(EFPIA), the Ministry of Health, Labour and Welfare, the 1986 Japan Pharmaceutical Manufacturers Association(JPMA), the Food and Drug Administration(FDA), and the Pharmaceutical Research and Manufacturers of America(PhRMA).
The ICH process consists of five steps:
Step 1: Expert Working Group consensus building
Steering Committee(SC) adopts a concept paper as a new topic, the process of consensus building begins.A rapporteuris usually designated from the industry members of the respective six-member Expert Working Group(EWG). This EWG consists of regulatory and industry parties (one voting member of each party and region), and observers. The rapporteur prepares an initial draft of the guideline, based on the objectives set out in the concept paper, and in consultation with experts designated to the EWG. The initial draft and successive revisions are circulated for comments within the EWG.Usually, the EWG consultation is carried out by correspondence. Face-to-face meetings of the EWG will normally only take place during the biannual SC meetings. Interim reports are made at each meeting of the SC.If consensus is reached the EWG will sign the "Step 2 Experts Signoff" sheet and submit it to the SC to request adoption.If there is no agreement in the EWG within the time frame the SC may extend the time frame, suspend or abandon the harmonization project.
Step 2: Confirmation of EWG consensus by the SC
Step 2 is reached when the SC agrees, based on the report of the EWG, that there is sufficient scientific consensus on the technical issues for the draft guideline. This text is signed off by the SC as "Step 2 Final Document".
Step 3: Regulatory consultation and discussionThe draft becomes subject of consultation in the three regions. It is published in the European Union (as draft CHMP or CVMP guideline), Japan (after translation by
MHLW), and the USA (as draft guideline in the Federal Register) and everybody within these regions can comment on it. There is also an opportunity for companies, associations and authorities in non-ICH regions to comment on the draft, which is distributed by IFPMAand WHO. After obtaining all consultation results, the EWG will be resumed. A new rapporteur will be appointed from the regulatory party, preferably from the same region as the previous rapporteur. The same procedure described in Step 1 is used to address the consultation results into the "Step 2 Final Document". The draft document to be generated as a result of the Step 3 phase is called Step 4 Experts Document.If industry and regulatory EWG members agree on the alterations as a result of the consultation, the Step 4 Experts Document is signed by the EWG regulatory experts only ("Step 4 Experts Signoff") and submitted to the SC to request adoption as Step 4 of the ICH process.If there is no agreement in the EWG within the time frame the SC may extend the time frame, abandon the current draft and resume the process from Step 1, suspend or abandon the harmonization project.
Step 4: Adoption of an ICH harmonised tripartite guideline
Step 4 is reached when the SC agrees that there is sufficient scientific consensus on the technical issues. If one industry party has strong objections to the adoption of the guideline due to deviations of the revised draft from the original consensus the regulatory parties may agree that a revised document should be submitted for further consultation. In this case, the EWG discussion may be resumed.The Step 4 Final Document is signed off by the SC signatories for the regulatory parties of ICH as an
ICH Harmonised Tripartite Guideline.
Step 5: Implementation
The ICH Harmonised Tripartite Guideline moves immediately to the final step of the process that is the regulatory implementation. This step is carried out according to the same national/regional procedures that apply to other regional regulatory guidelines and requirements, in the
European Union, Japan, and the United States.Information on the regulatory action taken and implementation dates are reported back to the SC and published by the ICH Secretariat on the ICH website.
Australia New Zealand Therapeutic Products Authority
Common Technical Document(CTD)
Council for International Organizations of Medical Sciences
Essential drugs and medicines policy- WHO's program
Harmonization in clinical trials
Health Sciences Authority- Singapore
International Conference of Drug Regulatory Authorities
Good clinical practice(GCP)
National Pharmaceutical Control Bureau- Malaysia
National pharmaceuticals policy
Regulation of therapeutic goods
State Food and Drug Administration- China
Uppsala Monitoring Centre
* [http://www.ich.org Official ICH website]
Wikimedia Foundation. 2010.
Look at other dictionaries:
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use — Das Ziel der International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) ist die Harmonisierung der Beurteilungskriterien von Human Arzneimitteln als Basis der Arzneimittelzulassung… … Deutsch Wikipedia
International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products — Das Ziel der International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) ist die Harmonisierung der Anforderungen an Arzneimittelzulassungen von Tierarzneimitteln. Es ist ein… … Deutsch Wikipedia
Committee for Medicinal Products for Human Use — Der Ausschuss für Humanarzneimittel (engl.: Committee for Medicinal Products for Human Use, offizielle Abkürzung: CHMP) ist ein wissenschaftlicher Ausschuss der Europäischen Arzneimittelagentur (EMEA). Der CHMP bereitet die Bewertungen der… … Deutsch Wikipedia
National pharmaceuticals policy — A National Pharmaceuticals Policy is one that aims at ensuring that people get good quality drugs at the lowest possible price, and that doctors prescribe the minimum of required drugs in order to treat the patient s illness. The pioneers in this … Wikipedia
Specification (technical standard) — Specification redirects here. For other uses, see Specification (disambiguation). A specification (often abbreviated as spec) is an explicit set of requirements to be satisfied by a material, product, or service. Should a material, product or… … Wikipedia
Council for International Organizations of Medical Sciences — The Council for International Organizations of Medical Sciences (CIOMS) is an international, nongovernmental, not for profit organization established jointly by WHO and UNESCO in 1949. CIOMS serves the scientific interests of the international… … Wikipedia
Common Technical Document — The Common Technical Document (CTD) is a set of specification for application dossier for the registration of Medicines and designed to be used across Europe, Japan and the United States. It was developed by the European Medicines Agency (EMA,… … Wikipedia
European Forum for Good Clinical Practice — The European Forum for Good Clinical Practices (EFGCP) is a European think tank which works on the ethical, regulatory, and scientific framework of clinical research in Europe. The EFGCP is committed to the development of the standards for the… … Wikipedia
Common Technical Document — Das Common Technical Document (CTD) ist ein vorgeschriebenes Dokumentenformat, in dem ein Pharmaunternehmen die pharmazeutische Qualität, Unbedenklichkeit und Wirksamkeit eines Arzneimittels im Rahmen der Arzneimittelzulassung dokumentieren und… … Deutsch Wikipedia
Canadian Agency for Drugs and Technologies in Health — The Canadian Agency for Drugs and Technologies in Health (CADTH) is a national body that provides Canada’s federal, provincial and territorial health care decision makers with credible, impartial advice and evidence based information about the… … Wikipedia